rituximab Turanci (Q412323)

Daga Wikidata
Jump to navigation Jump to search
pharmaceutical drug Turanci
gyara
Language Label Description Also known as
Hausa
Ba suna a kai
Ba'a bayyana ma'ana ba
    Turanci
    rituximab
    pharmaceutical drug
    • IDEC-102
    • RG-105
    • IDEC-C2B8
    • AntiCD20
    • R-105 IDEC-102
    • Ig gamma-1 chain C region
    • Rituxan
    • Mabthera

    Statements

    iri
    type of chemical entity Turanci
    0 references
    Ƙaramin ɓangare na
    chemical compound Turanci
    0 references
    amfani
    magani
    1 reference
    laƙabi
    Rituximab (Turanci)
    stated in Turanci
    DrugBank Turanci
    harshen aiki ko suna
    Turanci
    ranar wallafa
    17 Nuwamba 2015
    DrugBank ID Turanci
    00073
    image of molecular model or crystal lattice model Turanci
    Rituximab.png
    1,020 × 625; 262 KB
    depicts Turanci
    ribbon diagram Turanci
    0 references
    medical condition treated Turanci
    B-cell lymphoma Turanci
    2 references
    stated in Turanci
    NDF-RT Turanci
    NDF-RT ID Turanci
    N0000148560
    harshen aiki ko suna
    Turanci
    retrieved Turanci
    13 Disamba 2016
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    hairy cell leukemia Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    granulomatosis with polyangiitis Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    chronic lymphocytic leukemia Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    Ciwon Nephrotic
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    polymyositis Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    post-transplant lymphoproliferative disorder Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    lymphoma Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    diffuse large B-cell lymphoma Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    lupus nephritis Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    sankaran bargo
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    interstitial lung disease Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    Waldenström macroglobulinemia Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    thrombotic thrombocytopenic purpura Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    graft-versus-host disease Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    microscopic polyangiitis Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    cryoglobulinemia Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    non-Hodgkin lymphoma Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    myasthenia gravis Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    neuromyelitis optica Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    arthritis Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    thrombocytopenia Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    Sjögren's syndrome Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    membranous glomerulonephritis Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    central nervous system lymphoma Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    mantle cell lymphoma Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    autoimmune hemolytic anemia Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    bullous pemphigoid Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    Sclerosis da yawa
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    Castleman's disease Turanci
    1 reference
    stated in Turanci
    Drug Indications Extracted from FAERS Turanci
    retrieved Turanci
    2 Oktoba 2018
    AntiMOG associated encephalomyelitis Turanci
    0 references
    legal status (medicine) Turanci
    boxed warning Turanci
    1 reference
    adireshin manazarta
    https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802
    laƙabi
    FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (Turanci)
    has characteristic Turanci
    biopharmaceutical Turanci
    1 reference
    laƙabi
    Rituximab (Turanci)
    stated in Turanci
    DrugBank Turanci
    harshen aiki ko suna
    Turanci
    ranar wallafa
    17 Nuwamba 2015
    DrugBank ID Turanci
    00073
    subject has role Turanci
    immunologic factor Turanci
    1 reference
    stated in Turanci
    Medical Subject Headings Turanci
    MeSH descriptor ID Turanci
    D000069283
    retrieved Turanci
    15 Maris 2018
    disease-modifying antirheumatic drug Turanci
    1 reference
    stated in Turanci
    Medical Subject Headings Turanci
    MeSH descriptor ID Turanci
    D000069283
    retrieved Turanci
    15 Maris 2018
    immunological antineoplastic agent Turanci
    1 reference
    stated in Turanci
    Medical Subject Headings Turanci
    MeSH descriptor ID Turanci
    D000069283
    retrieved Turanci
    15 Maris 2018
    essential medicine Turanci
    0 references
    monoclonal antibody Turanci
    1 reference
    stated in Turanci
    DrugBank Turanci
    DrugBank ID Turanci
    00073
    harshen aiki ko suna
    Turanci
    laƙabi
    Rituximab (Turanci)
    ranar wallafa
    17 Nuwamba 2015
    has part(s) Turanci
    C
    0 references
    Commons category Turanci
    Rituximab
    0 references

    Identifiers

    NL CR AUT ID Turanci
    ph270796
    subject named as Turanci
    rituximab
    0 references
    CAS Registry Number Turanci
    174722-31-7
    2 references
    stated in Turanci
    DrugBank Turanci
    DrugBank ID Turanci
    00073
    laƙabi
    Rituximab (Turanci)
    ranar wallafa
    17 Nuwamba 2015
    stated in Turanci
    ChemIDplus Turanci
    laƙabi
    Rituximab (Turanci)
    retrieved Turanci
    24 Afirilu 2016
    adireshin manazarta
    http://chem.sis.nlm.nih.gov/chemidplus/rn/174722-31-7
    ChEMBL ID Turanci
    CHEMBL1201576
    1 reference
    stated in Turanci
    ChEMBL Turanci
    ChEMBL ID Turanci
    CHEMBL1201576
    harshen aiki ko suna
    Turanci
    laƙabi
    Rituximab (Turanci)
    retrieved Turanci
    19 Janairu 2016
    HSDB ID Turanci
    7455
    1 reference
    stated in Turanci
    Hazardous Substances Data Bank Turanci
    HSDB ID Turanci
    7455
    ranar wallafa
    28 Oktoba 2019
    laƙabi
    RITUXIMAB (Turanci)
    retrieved Turanci
    10 Mayu 2021
    DSSTox substance ID Turanci
    DTXSID5040910
    0 references
    LiverTox ID Turanci
    Rituximab
    0 references
    EC number Turanci
    695-706-4
    1 reference
    stated in Turanci
    ECHA Substance Infocard database Turanci
    ECHA Substance Infocard ID Turanci
    100.224.382
    retrieved Turanci
    27 Disamba 2018
    laƙabi
    Immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal IDEC-C2B8 .gamma.1-chain), disulfide with human-mouse monoclonal IDEC-C2B8 .kappa.-chain, dimer (Turanci)
    quotation Turanci
    CAS no.: 174722-31-7 (Turanci)
    ECHA Substance Infocard ID Turanci
    100.224.382
    1 reference
    stated in Turanci
    ECHA Substance Infocard database Turanci
    ECHA Substance Infocard ID Turanci
    100.224.382
    retrieved Turanci
    27 Disamba 2018
    laƙabi
    Immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal IDEC-C2B8 .gamma.1-chain), disulfide with human-mouse monoclonal IDEC-C2B8 .kappa.-chain, dimer (Turanci)
    quotation Turanci
    CAS no.: 174722-31-7 (Turanci)
    Lambar ATC
    L01XC02
    1 reference
    stated in Turanci
    DrugBank Turanci
    DrugBank ID Turanci
    00073
    harshen aiki ko suna
    Turanci
    laƙabi
    Rituximab (Turanci)
    ranar wallafa
    17 Nuwamba 2015
    Guide to Pharmacology Ligand ID Turanci
    6780
    0 references
    MeSH descriptor ID Turanci
    D000069283
    subject named as Turanci
    Rituximab
    0 references
    RxNorm ID Turanci
    121191
    1 reference
    stated in Turanci
    NDF-RT Turanci
    NDF-RT ID Turanci
    N0000148560
    retrieved Turanci
    26 Faburairu 2018
    DrugBank ID Turanci
    DB00073
    0 references
    UNII Turanci
    4F4X42SYQ6
    2 references
    stated in Turanci
    NDF-RT Turanci
    NDF-RT ID Turanci
    N0000148560
    laƙabi
    RITUXIMAB (Turanci)
    retrieved Turanci
    19 Janairu 2016
    stated in Turanci
    ChemIDplus Turanci
    laƙabi
    Rituximab (Turanci)
    retrieved Turanci
    24 Afirilu 2016
    adireshin manazarta
    http://chem.sis.nlm.nih.gov/chemidplus/rn/174722-31-7
    MedlinePlus drug identifier Turanci
    a607038
    0 references
    NDF-RT ID Turanci
    N0000148560
    1 reference
    stated in Turanci
    NDF-RT Turanci
    NDF-RT ID Turanci
    N0000148560
    harshen aiki ko suna
    Turanci
    laƙabi
    RITUXIMAB (Turanci)
    retrieved Turanci
    19 Janairu 2016
    KEGG ID Turanci
    D02994
    1 reference
    an ɗauko daga
    English Wikipedia Turanci
    DeCS ID Turanci
    55982
    0 references
    Encyclopedia of China (Third Edition) ID Turanci
    631054
    subject named as Turanci
    利妥昔单抗
    0 references
    Freebase ID Turanci
    /m/04k6q7
    1 reference
    stated in Turanci
    Freebase Data Dumps Turanci
    ranar wallafa
    28 Oktoba 2013
    Microsoft Academic ID Turanci
    2777615152
    0 references
    2780653079
    0 references
    Quora topic ID Turanci
    Rituximab
    1 reference
    stated in Turanci
    Quora
    UK Parliament thesaurus ID Turanci
    11462
    subject named as Turanci
    Rituximab
    0 references
    WikiProjectMed ID Turanci
    Rituximab
    0 references
    WikiSkripta article ID Turanci
    52724
    0 references
     
    gyara
    gyara
      gyara
        gyara
          gyara
            gyara
              gyara
                gyara
                  gyara
                  Daga "https://www.wikidata.org/w/index.php?title=Q412323&oldid=2256003206"